1. Scrip
  2. >>Business

With 2023's Largest Indian IPO, Mankind Listing Watched; GPCR-Based Candidate Enters Trials

Transplant, Oncology Divisions Planned

 
• By Vibha Ravi

Scrip takes a look at what a listing of Mankind Pharma, which has thrice the revenues of Pfizer’s India unit and the fourth largest domestic pharma sales, would mean. A GPCR-based candidate against type-2 diabetes and obesity is in Phase I trials and a search on India’s trial registry reveals a study for an ayurvedic preparation against diabetes

IPO Concept
Mankind's IPO Is Indian Pharma's Biggest In 2023 So Far • Source: Shutterstock

It’s not every day that a company the size of Mankind Pharma Ltd. makes a debut on Indian stock markets. With three times the operational revenue of Pfizer’s India unit, the fourth largest Indian pharmaceutical company by domestic sales is set to list on Indian stock exchanges on 8 May.

The last time a comparable pharma firm made an initial public offering (IPO) was nearly two and a half years back when Shanghai Fosun Pharmaceutical (Group) Co., Ltd. listed subsidiary Gland Pharma Ltd. on Indian stock exchanges

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.